Application 210933

Type: NDA
Sponsor: KALA PHARMS INC

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	EYSUVIS	LOTEPREDNOL ETABONATE	SOLUTION;OPHTHALMIC	0.25%	Yes	No

Source provenance: Browse the complete Orange Book source catalog · source snapshot 42.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N210933-001	EYSUVIS	LOTEPREDNOL ETABONATE	0.25%	SUSPENSION/DROPS / OPHTHALMIC		RLD, RS	2020-10-26

Orange Book patents#

Current patent rows page 1 of 1 · 17 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N210933-001	10058511	2033-05-03	U-2492	Drug product	2020-11-20
N210933-001	10646436	2033-05-03		Drug product	2020-11-20
N210933-001	10688045	2033-05-03		Drug product	2020-11-20
N210933-001	10857096	2033-05-03	U-2985		2020-12-28
N210933-001	10940108	2033-05-03	U-2985		2021-03-30
N210933-001	10945948	2033-05-03	U-2985		2021-03-30
N210933-001	10993908	2033-05-03	U-3117		2021-05-26
N210933-001	11219596	2033-05-03	U-2985		2022-01-21
N210933-001	11596599	2033-05-03	U-2985		2023-03-31
N210933-001	11642317	2033-05-03		Drug product	2023-05-31
N210933-001	11872318	2033-05-03		Drug product	2024-02-01
N210933-001	12115246	2033-05-03	U-2985	Drug product	2024-11-08
N210933-001	9056057	2033-05-03	U-2491	Drug product	2020-11-20
N210933-001	9393213	2033-05-03		Drug product	2020-11-20
N210933-001	9532955	2033-05-03	U-2491		2020-11-20
N210933-001	9737491	2033-05-03	U-2492		2020-11-20
N210933-001	9827191	2033-05-03	U-2985	Drug product	2020-11-20

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-08-18 06:07:40	2026-07	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`4b0b4de00fa7…`
2022-03-09 01:35 UTC	2022-03	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`8869cabd3fbd…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`a72a2bbeb626…`
2023-10-25 00:34 UTC · 2 captures of this ZIP	2023-10	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`9b2671bbb829…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`a67488948f0b…`
2023-06-13 01:57 UTC · 3 captures of this ZIP	2023-06	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`3f0d92c62455…`
2023-05-13 08:27 UTC	2023-05	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`053a50430f4f…`
2023-01-26 05:58 UTC	2023-01	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`cb3db0bc1861…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N210933-001	EYSUVIS	0.25%	SUSPENSION/DROPS / OPHTHALMIC	RLD, RS	2020-10-26	`a50c72e98297…`

Observed Orange Book patent history#

Patent history page 1 of 14 · 543 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-08-18 06:07:40	2026-07	N210933-001	10058511	2033-05-03	U-2492	Drug product	2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	10646436	2033-05-03		Drug product	2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	10688045	2033-05-03		Drug product	2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	10857096	2033-05-03	U-2985		2020-12-28	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	10940108	2033-05-03	U-2985		2021-03-30	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	10945948	2033-05-03	U-2985		2021-03-30	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	10993908	2033-05-03	U-3117		2021-05-26	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	11219596	2033-05-03	U-2985		2022-01-21	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	11596599	2033-05-03	U-2985		2023-03-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	11642317	2033-05-03		Drug product	2023-05-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	11872318	2033-05-03		Drug product	2024-02-01	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	12115246	2033-05-03	U-2985	Drug product	2024-11-08	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	9056057	2033-05-03	U-2491	Drug product	2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	9393213	2033-05-03		Drug product	2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	9532955	2033-05-03	U-2491		2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	9737491	2033-05-03	U-2492		2020-11-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N210933-001	9827191	2033-05-03	U-2985	Drug product	2020-11-20	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10058511	2033-05-03	U-2492	Drug product	2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10646436	2033-05-03		Drug product	2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10688045	2033-05-03		Drug product	2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10857096	2033-05-03	U-2985		2020-12-28	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10940108	2033-05-03	U-2985		2021-03-30	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10945948	2033-05-03	U-2985		2021-03-30	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	10993908	2033-05-03	U-3117		2021-05-26	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	11219596	2033-05-03	U-2985		2022-01-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	11596599	2033-05-03	U-2985		2023-03-31	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	11642317	2033-05-03		Drug product	2023-05-31	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	11872318	2033-05-03		Drug product	2024-02-01	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	12115246	2033-05-03	U-2985	Drug product	2024-11-08	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	9056057	2033-05-03	U-2491	Drug product	2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	9393213	2033-05-03		Drug product	2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	9532955	2033-05-03	U-2491		2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	9737491	2033-05-03	U-2492		2020-11-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N210933-001	9827191	2033-05-03	U-2985	Drug product	2020-11-20	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	10058511	2033-05-03	U-2492	Drug product	2020-11-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	10646436	2033-05-03		Drug product	2020-11-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	10688045	2033-05-03		Drug product	2020-11-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	10857096	2033-05-03	U-2985		2020-12-28	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	10940108	2033-05-03	U-2985		2021-03-30	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N210933-001	10945948	2033-05-03	U-2985		2021-03-30	`31067a03dcf5…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N210933-001	NP	2023-10-26	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N210933-001	NP	2023-10-26	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N210933-001	NP	2023-10-26	`4b0b4de00fa7…`
2022-03-09 01:35 UTC	2022-03	N210933-001	NP	2023-10-26	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N210933-001	NP	2023-10-26	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N210933-001	NP	2023-10-26	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N210933-001	NP	2023-10-26	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N210933-001	NP	2023-10-26	`8869cabd3fbd…`
2023-12-20 04:57 UTC	2023-12	N210933-001	NP	2023-10-26	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N210933-001	NP	2023-10-26	`a72a2bbeb626…`
2023-10-25 00:34 UTC · 2 captures of this ZIP	2023-10	N210933-001	NP	2023-10-26	`9b2671bbb829…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	N210933-001	NP	2023-10-26	`a67488948f0b…`
2023-06-13 01:57 UTC · 3 captures of this ZIP	2023-06	N210933-001	NP	2023-10-26	`3f0d92c62455…`
2023-05-13 08:27 UTC	2023-05	N210933-001	NP	2023-10-26	`053a50430f4f…`
2023-01-26 05:58 UTC	2023-01	N210933-001	NP	2023-10-26	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N210933-001	NP	2023-10-26	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	N210933-001	NP	2023-10-26	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	N210933-001	NP	2023-10-26	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N210933-001	NP	2023-10-26	`cb3db0bc1861…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Eysuvis	LOTEPREDNOL ETABONATE	ALCON LABORATORIES, INC.	a2169d82-4275-4ab6-a1c3-c274080b815c	2025-03-11	Warnings, Adverse reactions	Exact identifier application applno (NDA): 210933 application number: NDA210933 ndc (product): 71571-333

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 4 matching rows.

NDC, Name, Nonproprietary name table
NDC	Name	Nonproprietary name	Labeler	Marketing category	Status
71571-333	Eysuvis	loteprednol etabonate	Kala Pharmaceuticals, Inc.	NDA	Current
71571-333	Eysuvis	loteprednol etabonate	ALCON LABORATORIES, INC.	NDA	Current
71571-333	Eysuvis	loteprednol etabonate	Kala Pharmaceuticals, Inc.	NDA	Current
71571-333	Eysuvis	loteprednol etabonate	Kala Pharmaceuticals, Inc.	NDA	Current

Documents#

Document, Submission type, Date table
Document	Submission type	Date
68550	ORIG	2021-09-08
65122	ORIG	2020-11-02
65087	ORIG	2020-10-30